19.12.2014 SARTORIUS AG  DE0007165607

DGAP-Adhoc: SARTORIUS AG: Sartorius to Sell Its Industrial Technologies Division to Minebea Co., Ltd.


 
SARTORIUS AG / Key word(s): Disposal 19.12.2014 19:16 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Goettingen, December 19, 2014 - Sartorius, a leading international laboratory and pharmaceutical equipment provider, is selling its Industrial Technologies Division (Intec) to the Japanese Minebea Co., Ltd. (Minebea) and their partner, the Development Bank of Japan Inc. The respective contract was signed today. The sales price will be determined as a multiple of the Intec division's 2014 operating profit and be fixed in early 2015. The contractual parties agreed on a 7.5 multiple on the division's 2014 operating EBITDA. The transaction is subject to customary closing conditions, including regulatory clearance by the antitrust authorities, and is expected to close in the first quarter of 2015. In fiscal 2013, the Intec Division earned sales revenue of 102 million euros and achieved an underlying EBITDA margin of 10.1%. Conference call and webcast Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, will discuss the transaction with analysts and investors on Monday, December 22, 2014, at 3:30 p.m. Central European Time (CET) in a teleconference. You may dial into the teleconference starting at 3:20 p.m. CET at the following numbers: Germany: +49(0)69 2222 10640 France: +33(0)1 76 77 22 40 UK: +44(0)20 3427 1923 USA: +1646 254 3387 The dial-in code is as follows: 7586730; to view the webcast, log onto: http://www.sartorius.de/de/konzern/investor-relations/sartorius-ag/ This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected. Contact Petra Kirchhoff | Vice President of Corporate Communications +49 (0)551.308.1686 | [email protected] 19.12.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: SARTORIUS AG Weender Landstraße 94 - 108 37075 Göttingen Germany Phone: +49.(0)551-308.0 Fax: +49.(0)551-308.3289 E-mail: [email protected] Internet: www.sartorius.com ISIN: DE0007165607, DE0007165631 WKN: 716560 , 716563 Listed: Regulierter Markt in Frankfurt (Prime Standard), Hannover; Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1.404,57 1.566,03 1.826,97 2.335,66 3.449,22 4.174,70 3.395,70
EBITDA1,2 353,20 405,00 495,80 636,70 1.134,26 1.410,40 962,70
EBITDA-Marge3 25,15 25,86 27,14 27,26 32,89 33,78
EBIT1,4 219,36 298,61 335,66 456,11 903,16 1.070,00 503,90
EBIT-Marge5 15,62 19,07 18,37 19,53 26,18 25,63 14,84
Jahresüberschuss1 159,33 197,48 218,74 299,56 426,98 655,40 290,00
Netto-Marge6 11,34 12,61 11,97 12,83 12,38 15,70 8,54
Cashflow1,7 206,51 244,52 377,19 511,53 865,81 734,20 853,60
Ergebnis je Aktie8 2,11 2,56 3,06 4,37 8,08 9,57 4,94
Dividende8 0,51 0,61 0,35 0,70 1,25 1,43 0,45
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: -

INVESTOR-INFORMATIONEN
©boersengefluester.de
Sartorius ST
WKN Kurs in € Einschätzung Börsenwert in Mio. €
716560 275,500 Halten 23.482,37
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
45,16 39,18 1,15 63,35
KBV KCV KUV EV/EBITDA
10,23 24,17 6,92 26,55
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,43 0,73 0,26 28.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
18.04.2024 19.07.2024 17.10.2024 16.02.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
5,43% 6,92% 3,96% -13,91%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SARTORIUS AG  ISIN: DE0007165607 können Sie bei EQS abrufen


Medtech , 716560 , SRT , XETR:SRT